AnaptysBio (ANAB) Revenue & Revenue Breakdown
AnaptysBio Revenue Highlights
Latest Revenue (Y)
$91.28M
Latest Revenue (Q)
$27.77M
AnaptysBio Revenue by Period
AnaptysBio Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $91.28M | 432.03% |
| 2023-12-31 | $17.16M | 66.78% |
| 2022-12-31 | $10.29M | -83.72% |
| 2021-12-31 | $63.17M | -15.77% |
| 2020-12-31 | $75.00M | 837.50% |
| 2019-12-31 | $8.00M | 60.00% |
| 2018-12-31 | $5.00M | -50.00% |
| 2017-12-31 | $10.00M | -40.06% |
| 2016-12-31 | $16.68M | -5.05% |
| 2015-12-31 | $17.57M | 10.94% |
| 2014-12-31 | $15.84M | 188.86% |
| 2013-12-31 | $5.48M | - |
AnaptysBio generated $91.28M in revenue during NA 2024, up 432.03% compared to the previous quarter, and up 1141.00% compared to the same period a year ago.
AnaptysBio Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-03-31 | $27.77M | -35.59% |
| 2024-12-31 | $43.11M | 43.63% |
| 2024-09-30 | $30.02M | 173.60% |
| 2024-06-30 | $10.97M | 52.82% |
| 2024-03-31 | $7.18M | -20.28% |
| 2023-12-31 | $9.01M | 171.40% |
| 2023-09-30 | $3.32M | -4.10% |
| 2023-06-30 | $3.46M | 151.82% |
| 2023-03-31 | $1.37M | -79.82% |
| 2022-12-31 | $6.81M | 426.53% |
| 2022-09-30 | $1.29M | 6.33% |
| 2022-06-30 | $1.22M | 25.36% |
| 2022-03-31 | $970.00K | -4.06% |
| 2021-12-31 | $1.01M | -95.16% |
| 2021-09-30 | $20.89M | -30.43% |
| 2021-06-30 | $30.03M | 166.98% |
| 2021-03-31 | $11.25M | -81.25% |
| 2020-12-31 | $60.00M | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | -100.00% |
| 2020-03-31 | $15.00M | 400.00% |
| 2019-12-31 | $3.00M | 100.00% |
| 2019-09-30 | - | -100.00% |
| 2019-06-30 | $5.00M | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | -100.00% |
| 2018-09-30 | $5.00M | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | -100.00% |
| 2017-12-31 | $3.00M | 100.00% |
| 2017-09-30 | - | -100.00% |
| 2017-06-30 | $7.00M | 100.00% |
| 2017-03-31 | - | -100.00% |
| 2016-12-31 | $2.75M | -14.31% |
| 2016-09-30 | $3.21M | -45.06% |
| 2016-06-30 | $5.85M | 20.22% |
| 2016-03-31 | $4.87M | 20.03% |
| 2015-12-31 | $4.05M | -10.67% |
| 2015-09-30 | $4.54M | -7.05% |
| 2015-06-30 | $4.88M | 19.16% |
| 2015-03-31 | $4.10M | 10.58% |
| 2014-12-31 | $3.71M | -39.80% |
| 2014-09-30 | $6.15M | - |
AnaptysBio generated $27.77M in revenue during Q1 2025, up -35.59% compared to the previous quarter, and up 308.40% compared to the same period a year ago.
AnaptysBio Revenue Breakdown
AnaptysBio Revenue Breakdown by Product
Quarterly Revenue by Product
| Product/Service | Jun 25 | Mar 25 |
|---|---|---|
| Research and Development Segment | $22.26M | $27.77M |
Latest
AnaptysBio's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: Research and Development Segment (100.00%).
AnaptysBio Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| MRVI | Maravai LifeSciences | $259.19M | $47.40M |
| ANAB | AnaptysBio | $91.28M | $27.77M |
| PHAT | Phathom Pharmaceuticals | $55.25M | $39.50M |
| KURA | Kura Oncology | $53.88M | $14.11M |
| EYPT | EyePoint Pharmaceuticals | $43.27M | $5.33M |
| TNGX | Tango Therapeutics | $42.07M | $3.18M |
| PGEN | Precigen | $3.92M | $856.00K |
| PROK | ProKidney | $76.00K | $221.00K |
| BBOT | BridgeBio Oncology Therapeutics | - | - |
| BCAX | Bicara Therapeutics | - | - |
| XNCR | Xencor | - | $32.73M |